Boost for GSK because the new bone marrow cancer drug drastically reduces the risk of death in patients
A cancer drug developed by GSK dramatically reduces the risk of death in patients, studies have shown.
A recent study found that the pharmaceutical giant’s Blenrep treatment reduced the risk of death by 42 percent in people suffering from multiple myeloma, a form of bone marrow cancer.
Although the disease is still incurable, the data showed that patients taking Blenrep would survive almost three years longer than those using existing treatments.
The results are a boost for GSK and boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines.
Blenrep could be worth more than £3 billion in annual sales to GSK if it comes to market.
The drug has been accepted for priority review by Chinese regulators, following a similar action last month by US watchdogs.
Trial success: GSK boss Emma Walmsley (pictured), who has tried to improve the pipeline of new drugs and vaccines
DIY INVESTMENT PLATFORMS
A. J. Bell
A. J. Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund trading and investment ideas
interactive investor
interactive investor
Invest for a fixed amount from € 4.99 per month
Sax
Sax
Get £200 back in trading fees
Trade 212
Trade 212
Free trading and no account fees
Affiliate links: If you purchase a product, This is Money may earn a commission. These deals have been chosen by our editors because we believe they are worth highlighting. This does not affect our editorial independence.